Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation

Inclusion Criteria: * About to undergo a primary liver transplant (including living donor, split liver) and are HCV positive. * Willing and capable of giving written consent for study participation * Expected to be capable of study participation for full 24 months post-transplantation. * Allograft biopsies will be possible * Expected use of calcineurin inhibitor (Neoral or Tacrolimus) as primary immunosuppression An immunosuppressive regimen consisting of a calcineurin inhibitor (Neoral or Tacrolimus) in combination with Simulect and MYCOPHENOLATE SODIUM Exclusion Criteria: * This is a multi-organ transplant or if the patient has previously been transplanted with any other organ. * This is a liver transplant from a non-heart beating donor. * This is an ABO incompatible transplant. * Patients with serum creatinine level \> 250 umol/L. * The recipient is seropositive for human immunodeficiency virus (HIV) antibodies. * Fulminant liver failure is the reason for transplant. * Patient is participating in other clinical trial involving exploratory drug * There is a known malignancy, or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin, or hepatocellular carcinoma less than 5 cm meeting Milan criteria for transplantation5. * The patient is being transplanted for hepatic malignancy with greater than 5 known lesions. * Severe coexisting disease is present or if any unstable medical condition is present which could affect the study objectives. * A female transplant candidate is pregnant, lactating or of childbearing potential and not practicing an acceptable method of contraception. * An unlicensed drug or therapy has been administered within one month prior to study entry or if such therapy is to be instituted post-transplantation.